ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

10 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

04 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

29 2 2024 17:00:33 提供 Nasdaq GlobeNewswire

Arcutis Announces Pricing of $150 Million Public Offering

28 2 2024 23:30:21 提供 Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

28 2 2024 16:10:00 提供 Nasdaq GlobeNewswire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

28 2 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 2 2024 05:50:12 提供 Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

16 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 2 2024 16:00:00 提供 Nasdaq GlobeNewswire